Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus CHILDREN S MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus CHILDREN S MOTRIN.
CHILDREN'S IBUPROFEN vs CHILDREN'S MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
2-4 hours in children; prolonged in neonates and hepatic impairment.
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Category D/X
Category C
NSAID
NSAID